Offers Claimed: 84
Downloaded Today: 164
NoIn general, Medicare plans do not cover this drug. This drug will likely be quite expensive and you may want to consider using a USARx discount instead of Medicare to find the best price for this prescription.
It depends. Which coverage stage are you in? Click on a tab below…
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your pregabalin prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Commonly reported side effects of pregabalin include: infection, ataxia, blurred vision, constipation, diplopia, dizziness, drowsiness, fatigue, headache, peripheral edema, tremor, weight gain, visual field loss, accidental injury, and xerostomia. Other side effects include: abnormal gait, abnormality in thinking, amnesia, arthralgia, asthenia, cognitive dysfunction, confusion, edema, neuropathy, sinusitis, speech disturbance, vertigo, visual disturbance, myasthenia, amblyopia, increased appetite, and twitching. See below for a comprehensive list of adverse effects.For the Consumer
Applies to pregabalin: oral capsule, oral solution, oral tablet extended release
Along with its needed effects, pregabalin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pregabalin:
Some side effects of pregabalin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
For Healthcare Professionals
Applies to pregabalin: oral capsule, oral solution, oral tablet extended releaseGeneral
The most common adverse reactions to this drug are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and "thinking abnormal" (primarily difficulty with concentration/attention); the more commonly reported events in pediatric patients include increased weight and increased appetite.Nervous system
Very common (10% or more): Dizziness (up to 37%), somnolence (up to 25%)
Common (1% to 10%): Neuropathy, ataxia, vertigo, incoordination, tremor, abnormal gait, headache, speech disorder, twitching
Uncommon (0.1% to 1%): Syncope, stupor, myoclonus, psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, hyporeflexia, hyperesthesia, burning sensation, ageusia, malaise
Rare (less than 0.1%): Convulsions, parosmia, hypokinesia, dysgraphia, shock, circumoral paresthesia, dysarthria, hyperalgesia, hyperkinesia, hypokinesia, hypotonia, myoclonus, neuralgia cerebellar syndrome, cogwheel rigidity, coma, dysautonomia, dystonia, encephalopathy, extrapyramidal syndrome, Guillain-Barre syndrome, hypalgesia, intracranial hypertension, torticollis, trismus, peripheral neuritis
Postmarketing reports: Coma
Among pediatric patients receiving this drug for the treatment of partial onset seizures, somnolence was reported in 21% of drug treated patients and 14% of placebo patients, occurring more frequently at higher doses. Somnolence includes related terms of lethargy, sluggishness, and hypersomnia.
Patients treated for central neuropathic pain due to spinal cord injury have experienced an increased incidence of CNS adverse effects, especially somnolence. This may be due to an additive effect with concomitant medications.
There are postmarketing reports of respiratory failure and coma in patients taking pregabalin and other CNS depressant agents.Cardiovascular
Very common (10% or more): Peripheral edema (up to 12%)
Common (1% to 10%): Chest pain
Uncommon (0.1% to 1%): Hypotension, hypertension, hot flushes, flushing, peripheral coldness, heart failure, postural hypotension, syncope
Rare (less than 0.1%): ST depressed, ventricular fibrillation
Frequency not reported: PR interval prolongation
In controlled clinical trials in adult patients, peripheral edema was reported in 6% of patients receiving this drug compared with 2% in the placebo group; 0.5% and 0.2% of patients withdrew due to peripheral edema in the drug treated group and the placebo group, respectively.
Analyses of clinical trial ECG data has shown the mean PR interval increase was 3 to 6 msec at doses greater than or equal to 300 mg/day. Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or those taking other PR prolonging medications, although the number of patients in the study was not sufficient to draw a definitive conclusion.Psychiatric
Common (1% to 10%): Confusion, euphoria, amnesia, nervousness, irritability, disorientation, insomnia, libido decreased, disturbance in attention, anxiety, depersonalization, stupor, abnormal thinking
Uncommon (0.1% to 1%): Cognitive disorder, mental impairment, abnormal dreams, agitation, apathy, aphasia, hallucinations, hostility
Rare (less than 0.1%): Delirium, delusions, manic reaction, paranoid reaction, personality disorder, psychotic depression, schizophrenic reaction, sleep disorder, disinhibitionHypersensitivity
Uncommon (0.1% to 1%): Hypersensitivity
Rare (0.01% to 0.1%): Allergic reaction, anaphylactic reactionDermatologic
Symptoms of angioedema have included swelling of the face, mouth (tongue, lips, and gums), and neck (throat and larynx). There have also been reports of life-threatening angioedema with respiratory compromise requiring emergency treatment. Therapy should be discontinued immediately in patients with these symptoms. Caution is recommended if this drug is used in patients who have had a previous episode of angioedema. Patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE inhibitors]) may be at increased risk of developing angioedema.
Common (1% to 10%): Ecchymosis, pruritus
Uncommon (0.1% to 1%): Angioedema, rash papular, urticaria, hyperhidrosis, abscess, cellulitis, alopecia, dry skin, eczema, hirsutism, skin ulcer, urticaria, vesiculobullous rash
Rare (less than 0.1%): Stevens Johnson syndrome, cold sweat, angioedema, exfoliative dermatitis, lichenoid dermatitis, melanosis, nail disorder, petechial rash, purpuric rash, pustular rash, skin atrophy, skin necrosis, skin nodule, subcutaneous noduleGastrointestinal
Common (1% to 10%): Dry mouth, constipation, nausea, vomiting, diarrhea, flatulence, abdominal distention, gastroenteritis
Uncommon (0.1% to 1%): Gastroesophageal reflux disease, salivary hypersecretion, hypoesthesia oral, cholecystitis, cholelithiasis, colitis, dysphagia, esophagitis, gastritis, GI hemorrhage, melena, mouth ulceration, pancreatitis, rectal hemorrhage, tongue edema
Rare (less than 0.1%): Ascites, granuloma
Postmarketing reports: Reduced lower gastrointestinal function events (e.g., intestinal obstruction, paralytic ileus, constipation)
Postmarketing reports of reduced lower gastrointestinal function events have been reported when co-administered with medications that have the potential to produce constipation, such as opioids.Genitourinary
Common (1% to 10%): Urinary incontinence, erectile dysfunction, impotence, urinary frequency, urinary incontinence
Uncommon (0.1% to 1%): Sexual dysfunction, ejaculation delayed, dysmenorrhea, breast pain, anorgasmia, albuminuria, dysuria, hematuria, kidney calculus, leukorrhea, menorrhagia, metrorrhagia, oliguria, urinary retention, urine abnormality, abnormal ejaculation, albuminuria, amenorrhea, dysmenorrhea, kidney calculus, menorrhagia, metrorrhagia, oliguria
Rare (less than 0.1%): Breast discharge, breast enlargement, gynecomastia, pelvic pain, balanitis, bladder neoplasm, cervicitis, dyspareunia, epididymitis, glomerulitis, ovarian disorderHematologic
Uncommon (0.1% to 1%): Neutropenia, blood creatine phosphokinase increased, alanine aminotransferase increased, aspartate aminotransferase increased, platelet count decreased, blood creatinine increased, blood potassium decreased, deep thrombophlebitis
Rare (less than 0.1%): White blood cell count decreased, anemia, eosinophilia, hypochromic anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocytopenia
Rare (0.01% to 0.1%): Myelofibrosis, polycythemia, prothrombin decreased, purpuraImmunologic
Very common (10% or more): Infection (up to 14%)
Common (1% to 10%): Influenza syndromeMusculoskeletal
Common (1% to 10%): Myasthenia, muscle cramp, arthralgia, back pain, pain in limb, cervical spasm, leg cramps
Uncommon (0.1% to 1%): Joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness, neck rigidity, arthrosis
Rare (less than 0.1%): Rhabdomyolysis, chondrodystrophy, generalized spasmOcular
Very common (10% or more): Visual field changes (13%)
Common (1% to 10%): Blurry vision, abnormal vision, diplopia, conjunctivitis
Uncommon (0.1% to 1%): Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, photosensitivity reaction, dry eye, lacrimation increased, eye irritation, retinal vascular disorder, abnormality of accommodation, blepharitis, dry eyes, eye hemorrhage, hyperacusis, photophobia, retinal edema
Rare (0.01% to 0.1%): Vision loss, keratitis, oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness, anisocoria, blindness, corneal ulcer, exophthalmos, extraocular palsy, iritis, keratitis, keratoconjunctivitis, miosis, mydriasis, night blindness, ophthalmoplegia, optic atrophy, papilledema, parosmia, ptosis, uveitisOther
Common (1% to 10%): Asthenia, accidental injury, face edema, pain, otitis media, tinnitus
Uncommon (less than 0.1% to 1%): Generalized edema, pain, pyrexia, chills, thirst
Rare (0.01% to 0.1%): Retroperitoneal fibrosis, retinal vascular disorder, taste loss, taste perversion
Frequency not reported: Withdrawal effects following rapid discontinuation
Some patients have reported withdrawal effects following abrupt/rapid discontinuation. These symptoms included insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea.Respiratory
There are postmarketing reports of respiratory failure and coma in patients taking pregabalin and other CNS depressant agents.
Common (1% to 10%): Dyspnea, bronchitis, nasopharyngitis
Uncommon (0.1% to 1%): Epistaxis, cough, nasal congestion, rhinitis, snoring, nasal dryness
Rare (less than 0.1%): Pulmonary edema, throat tightness, apnea, atelectasis, bronchiolitis, hiccup, laryngismus, lung fibrosis, yawn
Postmarketing reports: Respiratory failureMetabolic
Common (1% to 10%): Weight gain, edema, hypoglycemia, increased appetite
Uncommon (0.1% to 1%): Weight decreased, blood glucose increased
Rare (0.01% to 0.1%): Glucose tolerance decreased, urate crystalluriaHepatic
Uncommon (0.1% to 1%): Nephritis
Rare (0.01% to 0.1%): Acute kidney failure, pyelonephritisEndocrine
Postmarketing reports: Gynecomastia, breast enlargement
February 5, 2021
September 7, 2020
July 31, 2020
October 13, 2021
October 13, 2021
October 8, 2021